Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas
Open Access
- 7 December 2023
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 142 (23) , 1985-2001
Abstract
Constitutive mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) activity drives survival of malignant lymphomas addicted to chronic B-cell receptor signaling, oncogenic CARD11, or the API2-MALT1 (also BIRC3::MALT1) fusion oncoprotein. Although MALT1 scaffolding induces NF-κB–dependent survival signaling, MALT1 protease function is thought to augment NF-κB activation by cleaving signaling mediators and transcriptional regulators in B-cell lymphomas. However, the pathological role of MALT1 protease function in lymphomagenesis is not well understood. Here, we show that TRAF6 controls MALT1-dependent activation of NF-κB transcriptional responses but is dispensable for MALT1 protease activation driven by oncogenic CARD11. To uncouple enzymatic and nonenzymatic functions of MALT1, we analyzed TRAF6-dependent and -independent as well as MALT1 protease–dependent gene expression profiles downstream of oncogenic CARD11 and API2-MALT1. The data suggest that by cleaving and inactivating the RNA binding proteins Regnase-1 and Roquin-1/2, MALT1 protease induces posttranscriptional upregulation of many genes including NFKBIZ/IκBζ, NFKBID/IκBNS, and ZC3H12A/Regnase-1 in activated B-cell–like diffuse large B-cell lymphoma (ABC DLBCL). We demonstrate that oncogene-driven MALT1 activity in ABC DLBCL cells regulates NFKBIZ and NFKBID induction on an mRNA level via releasing a brake imposed by Regnase-1 and Roquin-1/2. Furthermore, MALT1 protease drives posttranscriptional gene induction in the context of the API2-MALT1 fusion created by the recurrent t(11;18)(q21;q21) translocation in MALT lymphoma. Thus, MALT1 paracaspase acts as a bifurcation point for enhancing transcriptional and posttranscriptional gene expression in malignant lymphomas. Moreover, the identification of MALT1 protease–selective target genes provides specific biomarkers for the clinical evaluation of MALT1 inhibitors.Keywords
This publication has 60 references indexed in Scilit:
- Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCLCancer Cell, 2012
- Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell linesProceedings of the National Academy of Sciences, 2011
- Cleavage of NIK by the API2-MALT1 Fusion Oncoprotein Leads to Noncanonical NF-κB ActivationScience, 2011
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphomaProceedings of the National Academy of Sciences, 2009
- Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cellsJournal of Experimental Medicine, 2009
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphomaNature, 2009
- Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profileOncogene, 2009
- A loss-of-function RNA interference screen for molecular targets in cancerNature, 2006
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000